BEHANDLUNG VON MULTIPLER SKLEROSE (MS) MIT CAMPATH-1H

European patent · EP3028718 · In force

Register entry

Publication number
EP3028718
Application number
EP15191491
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Sep 11, 2007
Published
Jun 8, 2016
Granted
Mar 23, 2022
Protection ends at the latest
Sep 10, 2027
Next annual fee due
Sep 30, 2027
IPC classes
A61K 39/395 (2006.01)
C07K 16/28 (2006.01)
Priority
US 844251 P 13.09.2006
EP 06090169 14.09.2006
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.09.2026 → 30.09.2027

    Published in Swissreg on 01.10.2026

  2. Oct 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.09.2025 → 30.09.2026

    Published in Swissreg on 01.10.2025

  3. Oct 3, 2024

    Change

    Published in Swissreg on 03.10.2024

  4. Oct 1, 2023

    Change

    Published in Swissreg on 01.10.2023

  5. Feb 17, 2023

    Change

    Published in Swissreg on 17.02.2023

  6. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  7. Mar 23, 2022

    Granted

    Published in Swissreg on 23.03.2022

Parties

Holder

Genzyme Corporation

50 Binney Street, Cambridge, MA 02142, US

Alcafleu Management GmbH & Co. KG

Lilienthalstrasse 4, 12529 Schönefeld OT Waltersdorf, DE

Inventor

SACHSE, Andreas

10709 Berlin, DE

MARGOLIN, David Harris

Sommerville, MA 02144, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.